SET8 inhibition preserves PTEN to attenuate kidney cell apoptosis in cisplatin nephrotoxicity

Xu Yang1, Yingjie Guan1, George Bayliss1

  • 1Rhode Island Hospital and Alpert Medical School, Brown University.

Research Square
|August 26, 2024
PubMed

Insights

SET8 inhibition protects against cisplatin-induced acute kidney injury (AKI) by preserving PTEN, which reduces DNA damage and restores autophagy in kidney cells.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Oncology

Background:

  • SET8, a histone methyltransferase, is linked to cancer but its role in acute kidney injury (AKI) is unclear.
  • Aberrant SET8 expression and H4K20me1 are observed in various tumors.

Purpose of the Study:

  • To investigate the role of SET8 in cisplatin-induced AKI.
  • To explore the therapeutic potential of SET8 inhibition in AKI.

Main Methods:

  • Cisplatin-induced AKI model in mice.
  • Treatment with SET8 inhibitor UNC0379 and SET8 siRNA.
  • Assessment of renal function, tubular injury, apoptosis, DNA damage response (DDR), and autophagy.
  • In vitro studies using renal proximal tubular epithelial cells (TKPTs).

Main Results:

  • SET8 and H4K20me1 were upregulated in cisplatin-induced AKI.
  • SET8 inhibition (UNC0379 or siRNA) improved renal function, reduced tubular damage, apoptosis, and DDR.
  • SET8 inhibition preserved PTEN expression and restored autophagy.
  • PTEN inhibition exacerbated cisplatin-induced damage, while PTEN overexpression ameliorated it.

Conclusions:

  • SET8 inhibition protects against cisplatin-induced AKI.
  • The protective mechanism involves PTEN preservation, leading to inhibition of DDR and restoration of autophagy.
  • SET8 is a potential therapeutic target for AKI.